MAPLE GROVE, Minn., April 26, 2012 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. today announced the launch of http://www.seizureclusterstudy.com, an informational website for individuals diagnosed with partial or generalized epilepsy who experience seizure clusters and are interested in participating in an ongoing Phase III clinical trial. The study, ARTEMIS1 (Acute Rescue Therapy in Epilepsy with Midazolam Intranasal Spray) is designed to evaluate the efficacy and safety of USL261, an investigational formulation of midazolam delivered intranasally, for the outpatient rescue treatment of seizure clusters. The website is the first of several planned initiatives to support the epilepsy community's participation in this important clinical trial.
The new website, http://www.seizureclusterstudy.com provides individuals suffering from or diagnosed with epilepsy and their caregivers information about ARTEMIS1 including key eligibility requirements. In addition to the website, interested individuals can call 1-866-372-0526 to learn more or to locate study centers.
"Clinical trials allow for the evaluation of safety and efficacy of investigational medications before they are made available to a broader population," said Pamela J. Davis, M.D., Sr. Director Medical Affairs, Medical Strategy, Upsher-Smith. "Clinical trials are an important part of the process to identify new treatment options for patients living with conditions such as seizure clusters where there is a significant need for new therapies. Upsher-Smith is working closely with the epilepsy community to complete ARTEMIS1 so that findings from the study can be interpreted and incorporated in the New Drug Application f
|SOURCE Upsher-Smith Laboratories, Inc.|
Copyright©2010 PR Newswire.
All rights reserved